Mirae Asset Global Investments Co. Ltd. Purchases 10,716 Shares of DaVita Inc. $DVA

Key Points

• Mirae Asset Global Investments acquired a new 10,716-share stake in DaVita during the third quarter, valued at approximately $1.87 million. Institutional investors collectively own 90.12% of the company.
• DaVita beat quarterly earnings and revenue estimates, reporting EPS of $3.82 versus a $3.57 consensus and revenue of $3.58 billion, up 4.6% year over year.
• Analyst sentiment is moderately positive: MarketBeat reports an average “Moderate Buy” rating and an average price target of $235.86; shares opened at $191.27.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,716 shares of the company's stock, valued at approximately $1,874,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Value Investment Professionals LLC lifted its stake in shares of DaVita by 2.0% during the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company's stock valued at $556,000 after buying an additional 50 shares in the last quarter. Kesler Norman & Wride LLC raised its holdings in DaVita by 0.8% during the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company's stock valued at $1,048,000 after acquiring an additional 55 shares during the period. State of Alaska Department of Revenue raised its holdings in DaVita by 1.9% during the 3rd quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company's stock valued at $560,000 after acquiring an additional 60 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in shares of DaVita by 4.1% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company's stock worth $426,000 after acquiring an additional 76 shares in the last quarter. Finally, CoreCap Advisors LLC lifted its position in shares of DaVita by 161.7% during the third quarter. CoreCap Advisors LLC now owns 157 shares of the company's stock worth $27,000 after acquiring an additional 97 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Stock Performance

Shares of DVA stock opened at $191.27 on Friday. The company has a market capitalization of $12.03 billion, a PE ratio of 14.08, a price-to-earnings-growth ratio of 0.48 and a beta of 0.87. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The business's fifty day moving average is $182.52 and its 200 day moving average is $178.61.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.57 by $0.25. DaVita had a negative return on equity of 225.93% and a net margin of 6.49%. The firm had revenue of $3.58 billion during the quarter, compared to the consensus estimate of $3.52 billion. During the same quarter last year, the company posted $2.51 EPS. The company's revenue for the quarter was up 4.6% on a year-over-year basis. On average, sell-side analysts forecast that DaVita Inc. will post 14.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on DVA shares. Wall Street Zen lowered DaVita from a "buy" rating to a "hold" rating in a report on Saturday, October 31st. UBS Group boosted their price objective on DaVita from $270.00 to $287.00 and gave the company a "buy" rating in a research note on Monday, November 2nd. Weiss Ratings upgraded DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, October 9th. Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. Finally, TD Cowen raised their target price on DaVita from $220.00 to $228.00 and gave the stock a "buy" rating in a research note on Monday, November 2nd. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $235.86.

About DaVita

DaVita Inc is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure.

The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets.

Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.